NASDAQ · TRML
Tourmaline Bio, Inc.
$47.98$0.00 (0.0%)
Tourmaline Bio, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.6% below the high.
Loading market information…
NASDAQ · PROC · USD
Stock price, earnings
Quote as of Mar 12, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Procaps Group S.A.’s quoted price sits in the lower half of its reported 52-week range, 73.25% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Procaps Group S.A.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Procaps Group S.A., established in Luxembourg in 1977, functions as a global pharmaceutical enterprise dedicated to the creation, production, and distribution of a broad spectrum of pharmaceutical solutions. The company manufactures and markets branded prescription medications addressing diverse therapeutic needs, including women's health, pain management, dermatological conditions, digestive disorders, growth and development, cardiovascular care, vision health, central nervous system ailments, and respiratory issues. In addition to prescription drugs, Procaps supplies a suite of products for hospital use, encompassing antibiotics, anticoagulants, personal protective equipment, immunosuppressants, oncology treatments, and analgesics. Its consumer healthcare division offers an extensive portfolio of over-the-counter (OTC) products across approximately eight primary therapeutic areas such as gastrointestinal health, skincare, cough and cold remedies, pain relievers, urological support, and a variety of vitamins, minerals, and dietary supplements. These offerings cover specific categories like anti-infectives, cardiovascular health, hormonal treatments, metabolic and endocrine support, nervous system medications, ophthalmic solutions, osteoarticular products, and more. Complementing its drug offerings, Procaps provides various diabetes management solutions, including blood glucose meters, telemonitoring devices, oral anti-diabetic medications, cosmeceuticals, and insulin delivery systems. The company also extends its expertise to third-party pharmaceutical companies through contract drug development and manufacturing services, with a particular specialization in soft gelatin capsule technologies.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:48 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $101.47M-5.61% vs estimate |
| Q3 2022 | Nov 14, 2022 | $0.22+69.23% vs estimate | $110.40M-6.4% vs estimate |
|---|
THE ANALYST VIEW
1 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$47.98$0.00 (0.0%)
Tourmaline Bio, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.6% below the high.
$5.50-$0.67 (-10.8%)
Graybug Vision, Inc.’s quoted price sits in the lower half of its reported 52-week range, 72.91% below the high.
$1.10+$0.01 (+0.92%)
Societal CDMO, Inc.’s quoted price sits in the upper half of its reported 52-week range, 14.06% below the high.
$2.35-$0.01 (-0.21%)
Augmedix, Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.48% below the high.
$0.77$0.00 (0.0%)
Genetic Technologies Limited’s quoted price sits in the lower half of its reported 52-week range, 78.69% below the high.
$20.65$0.00 (0.0%)
Opiant Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 24.52% below the high.
$9.60$0.00 (0.0%)
OptiNose, Inc.’s quoted price sits in the lower half of its reported 52-week range, 52.06% below the high.
$0.10-$0.00 (-0.21%)
Zomedica Corp.’s quoted price sits in the lower half of its reported 52-week range, 50.15% below the high.
